Abstract

Lipodystrophic syndrome is a major side effect of highly active antiviral therapy. Fat tissue redistribution is associated with changes in adipocyte gene expression and in circulating levels of adipocytokines involved in the development of insulin resistance. However, the evidence that HIV drugs accumulate into human adipocytes and have a direct effect on the expression of adipocyte-specific genes is still lacking. To address these questions, we used adipocytes derived from adult stem (hMADS) cells isolated from human adipose tissue. We showed by ELISA that two inhibitors of the HIV protease, lopinavir and ritonavir, accumulated at similar levels during the development of hMADS cells in adipocytes, whereas a non-nucleoside reverse transcriptase inhibitor, the nevirapine, accumulated at lower levels. Two fluorescent protease inhibitors then have been generated to investigate their subcellular localization. The data showed that HIV drugs accumulated into adipocytes and displayed various effects on hMADS cell-derived adipocytes. Indinavir, amprenavir, and nevirapine did not alter differentiation of precursor cells. In contrast, lopinavir, saquinavir, and ritonavir inhibited the development of preadipocytes into adipocytes. In adipocytes, amprenavir increased leptin expression and ritonavir was able to up-regulate tumor necrosis factor-alpha, interleukin 6, and leptin expression and down-regulate the expression of peroxisome proliferator-activated receptor gamma and adiponectin. Intracellular accumulation and localization of HIV drugs into human adipocytes strongly suggest that adipose tissues store these drugs. Because ritonavir can alter the expression of insulin resistance-related cytokines in human adipocytes in a way parallel to the situation observed in vivo upon treatment of HIV-infected patients, we propose that protease inhibitors participate in insulin resistance through a direct effect on adipocytes.

Highlights

  • Active antiretroviral therapy (HAART)1 combines treatment with three classes of anti-HIV drugs: 1) protease inhibitors (PIs); nucleoside reverse transcriptase inhibitors (NRTIs); and non-nucleoside reverse transcriptase inhibitors (NNRTIs)

  • Because ritonavir can alter the expression of insulin resistance-related cytokines in human adipocytes in a way parallel to the situation observed in vivo upon treatment of HIV-infected patients, we propose that protease inhibitors participate in insulin resistance through a direct effect on adipocytes

  • HIV Drugs Enter and Accumulate into Human-cultured Adipocytes—We first investigated by ELISA the ability of two PIs (RTV and LPV) and one NNRTI (NVP) to enter and accumulate in human adipocytes

Read more

Summary

HIV Drugs in Cultured Human Adipocytes

The increase of TNF␣ in obese subjects suggests a role of this cytokine in the development of insulin resistance [10]. A direct effect of HIV drugs on the development of human adipocytes and on the expression of insulin-resistant-related genes has not been demonstrated. Our laboratory has recently isolated from human adipose tissue adult stem cells able to differentiate at a high rate into adipocytes [11]. These cells are termed multipotent adipose-derived stem (hMADS) cells. We used hMADS cells to investigate the following: 1) the intracellular localization and accumulation of HIV drugs in undifferentiated and differentiated cells; 2) the effects of different PIs and nevirapine on adipocyte differentiation and on fully differentiated adipocytes; and 3) the ability of PIs to modify the expression of adipocytokines involved in the establishment of insulin resistance

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call